Pemetrexed-Induced Nephrogenic Diabetes Insipidus.
Pemetrexed-Induced Nephrogenic Diabetes Insipidus.
复制标题
培美曲塞诱发的肾性尿崩症。
DOI：
10.1053/j.ajkd.2016.04.016
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Bhalla,Vivek
中科院分区：
文献类型：
--
作者：
Fung,Enrica;Anand,Shuchi;Bhalla,Vivek
培美曲塞是一种被批准的抗代谢药物，目前广泛用于治疗局部晚期或转移性非鳞状非小细胞肺癌。虽然这种药物的处方信息中没有电解质异常的描述，但有几个病例报告指出，肾源性尿崩症与急性肾损伤有关。我们报告了一例肾源性尿崩症，但肾功能没有严重下降，并提出了一种孤立发现的机制。严重的高钠血症可导致脑病和渗透性脱髓鞘，我们的报告强调了在接受培美曲塞治疗的肺癌患者中仔细监测电解质和肾功能的重要性。
Pemetrexed is an approved antimetabolite agent, now widely used for treating locally advanced or metastatic nonsquamous non–small cell lung cancer. Although no electrolyte abnormalities are described in the prescribing information for this drug, several case reports have noted nephrogenic diabetes insipidus with associated acute kidney injury. We present a case of nephrogenic diabetes insipidus without severely reduced kidney function and propose a mechanism for the isolated finding. Severe hypernatremia can lead to encephalopathy and osmotic demyelination, and our report highlights the importance of careful monitoring of electrolytes and kidney function in patients with lung cancer receiving pemetrexed.